GNOM vs. BBH
Compare and contrast key facts about Global X Genomics & Biotechnology ETF (GNOM) and VanEck Vectors Biotech ETF (BBH).
GNOM and BBH are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. GNOM is a passively managed fund by Global X that tracks the performance of the Solactive Genomics Index. It was launched on Apr 5, 2019. BBH is a passively managed fund by VanEck that tracks the performance of the MVIS US Listed Biotech 25 Index. It was launched on Dec 20, 2011. Both GNOM and BBH are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Performance
GNOM vs. BBH - Performance Comparison
Loading graphics...
GNOM vs. BBH - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
GNOM Global X Genomics & Biotechnology ETF | -2.79% | 18.65% | -15.99% | -8.63% | -36.27% | -15.93% | 51.52% | 1.56% |
BBH VanEck Vectors Biotech ETF | 0.04% | 21.18% | -4.29% | 3.94% | -15.25% | 11.81% | 22.13% | 6.33% |
Returns By Period
In the year-to-date period, GNOM achieves a -2.79% return, which is significantly lower than BBH's 0.04% return.
GNOM
- 1D
- 1.02%
- 1M
- -6.22%
- YTD
- -2.79%
- 6M
- 12.23%
- 1Y
- 44.15%
- 3Y*
- -3.13%
- 5Y*
- -13.13%
- 10Y*
- —
BBH
- 1D
- 0.70%
- 1M
- -3.58%
- YTD
- 0.04%
- 6M
- 10.55%
- 1Y
- 23.57%
- 3Y*
- 5.92%
- 5Y*
- 1.84%
- 10Y*
- 6.42%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
GNOM vs. BBH - Expense Ratio Comparison
GNOM has a 0.50% expense ratio, which is higher than BBH's 0.35% expense ratio.
Return for Risk
GNOM vs. BBH — Risk / Return Rank
GNOM
BBH
GNOM vs. BBH - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology ETF (GNOM) and VanEck Vectors Biotech ETF (BBH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| GNOM | BBH | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.43 | 1.05 | +0.38 |
Sortino ratioReturn per unit of downside risk | 2.04 | 1.53 | +0.51 |
Omega ratioGain probability vs. loss probability | 1.26 | 1.20 | +0.06 |
Calmar ratioReturn relative to maximum drawdown | 2.25 | 2.00 | +0.25 |
Martin ratioReturn relative to average drawdown | 7.43 | 5.56 | +1.86 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| GNOM | BBH | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.43 | 1.05 | +0.38 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.39 | 0.09 | -0.48 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.29 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.13 | 0.27 | -0.40 |
Correlation
The correlation between GNOM and BBH is 0.78, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
GNOM vs. BBH - Dividend Comparison
GNOM's dividend yield for the trailing twelve months is around 1.41%, more than BBH's 0.51% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GNOM Global X Genomics & Biotechnology ETF | 1.41% | 1.37% | 0.00% | 0.00% | 0.00% | 0.03% | 0.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BBH VanEck Vectors Biotech ETF | 0.51% | 0.51% | 0.80% | 0.43% | 0.47% | 0.21% | 0.36% | 0.34% | 0.50% | 0.55% | 0.30% | 0.27% |
Drawdowns
GNOM vs. BBH - Drawdown Comparison
The maximum GNOM drawdown since its inception was -75.00%, roughly equal to the maximum BBH drawdown of -72.70%. Use the drawdown chart below to compare losses from any high point for GNOM and BBH.
Loading graphics...
Drawdown Indicators
| GNOM | BBH | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -75.00% | -72.70% | -2.30% |
Max Drawdown (1Y)Largest decline over 1 year | -18.17% | -10.47% | -7.70% |
Max Drawdown (5Y)Largest decline over 5 years | -72.29% | -39.86% | -32.43% |
Max Drawdown (10Y)Largest decline over 10 years | — | -39.86% | — |
Current DrawdownCurrent decline from peak | -59.83% | -12.15% | -47.68% |
Average DrawdownAverage peak-to-trough decline | -40.12% | -26.05% | -14.07% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.51% | 3.76% | +1.75% |
Volatility
GNOM vs. BBH - Volatility Comparison
Global X Genomics & Biotechnology ETF (GNOM) has a higher volatility of 10.76% compared to VanEck Vectors Biotech ETF (BBH) at 7.01%. This indicates that GNOM's price experiences larger fluctuations and is considered to be riskier than BBH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| GNOM | BBH | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.76% | 7.01% | +3.75% |
Volatility (6M)Calculated over the trailing 6-month period | 19.71% | 13.69% | +6.02% |
Volatility (1Y)Calculated over the trailing 1-year period | 31.21% | 22.72% | +8.49% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.65% | 21.47% | +12.18% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 34.30% | 22.27% | +12.03% |